Cargando…

P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY

Detalles Bibliográficos
Autores principales:	Ritchie, Ellen, L. Lin, Tara, F. Newell, Laura, K. Stuart, Robert, Solomon, Scott, Stone, Richard, Schiller, Gary, Wieduwilt, Matthew, Amy Ryan, Eileen, Dronamraju, Nalina, Lancet, Jeffrey, Cortes, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428687/ http://dx.doi.org/10.1097/01.HS9.0000968976.77539.68

Ejemplares similares

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML
por: Uy, Geoffrey L., et al.
Publicado: (2022)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
por: Mitchell, Joshua D., et al.
Publicado: (2023)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
por: Cortes, Jorge E., et al.
Publicado: (2021)

Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo
por: Vincelette, Nicole D., et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
por: Wang, Qi, et al.
Publicado: (2018)

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
por: Lin, Tara L., et al.
Publicado: (2019)

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML
por: Molica, Matteo, et al.
Publicado: (2022)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial
por: Cortes, Jorge E., et al.
Publicado: (2022)

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
por: Rautenberg, Christina, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
por: Urbantat, Ruth M., et al.
Publicado: (2021)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

Successful Treatment of Acute Myeloid Leukemia with CPX-351 in 2 Patients in the United Kingdom during the COVID-19 Pandemic
por: Munisamy, Sreetharan, et al.
Publicado: (2021)

Memorandum 517
por: Peyaud, B
Publicado: (1993)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
por: Fortin, Marie C., et al.
Publicado: (2023)

P486: REAL-WORLD EFFECTIVENESS AND SAFETY OF CPX-351 IN PATIENTS AGED <60 AND ≥60 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: CREST-UK POST-HOC ANALYSIS
por: Mehta, Priyanka, et al.
Publicado: (2023)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
por: Araie, Hiroaki, et al.
Publicado: (2023)

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
por: Fianchi, Luana, et al.
Publicado: (2023)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
por: Guolo, Fabio, et al.
Publicado: (2020)

PB1879: EFFICACY AND SAFETY OF CPX-351 COMPARED TO STANDARD OF CARE CHEMOTHERAPY IN A REAL-LIFE SETTING: SUPPORTING PREVIOUS EVIDENCE AND FACING NEW CHALLENGES
por: Manghisi, Beatrice, et al.
Publicado: (2023)

Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
por: Bernal, Teresa, et al.
Publicado: (2023)

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
por: Luca Morelli, Gian, et al.
Publicado: (2023)

P557: LIFETIME CLINICAL OUTCOMES OF CPX-351 VERSUS 7 + 3 MODELED FROM THE 5-YEAR RESULTS OF A RANDOMIZED PHASE 3 TRIAL FOR OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKAEMIA
por: Reifsnider, Odette, et al.
Publicado: (2023)

The two-component system CpxA/CpxR is critical for full virulence in Actinobacillus pleuropneumoniae
por: Liu, Feng, et al.
Publicado: (2022)

Placental Expression of miR-517a/b and miR-517c Contributes to Trophoblast Dysfunction and Preeclampsia
por: Anton, Lauren, et al.
Publicado: (2015)

Memorandum 351
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1983)

Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989-4993.
Publicado: (2023)

Interactions of the CpxA sensor kinase and cognate CpxR response regulator from Yersinia pseudotuberculosis
por: Thanikkal, Edvin J, et al.
Publicado: (2012)

The CpxA/CpxR Two-Component System Affects Biofilm Formation and Virulence in Actinobacillus pleuropneumoniae
por: Li, Huan, et al.
Publicado: (2018)

The Virulence Effect of CpxRA in Citrobacter rodentium Is Independent of the Auxiliary Proteins NlpE and CpxP
por: Giannakopoulou, Natalia, et al.
Publicado: (2018)

The CpxA/CpxR two-component system mediates regulation of Actinobacillus pleuropneumoniae cold growth
por: Yao, Qing, et al.
Publicado: (2022)

Effect of Ion Corrosion on 517 Phase Stability
por: Wang, Guijia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_op8t0ebtdbdlglr1p2eqb1sklm